{"id":"NCT01180296","sponsor":"Fetal Medicine Foundation","briefTitle":"Oral Progesterone for Prevention of Preterm Birth","officialTitle":"Prevention of Recurrent Preterm Birth With Micronized Progesterone","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-11","primaryCompletion":"2009-01","completion":"2009-01","firstPosted":"2010-08-12","resultsPosted":"2011-07-21","lastUpdate":"2019-02-18"},"enrollment":36,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Preterm Birth"],"interventions":[{"type":"DRUG","name":"oral micronized progesterone","otherNames":["Prometrium(TM)"]},{"type":"DRUG","name":"Identical Placebo tablet","otherNames":["Placebo"]}],"arms":[{"label":"Progesterone Group","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To evaluate whether daily oral micronized progesterone is effective in preventing recurrent spontaneous preterm birth (RSPB) and whether micronized progesterone use increases maternal serum progesterone levels.","primaryOutcome":{"measure":"Rate of Recurrent Preterm Birth","timeFrame":"Prior to 37 weeks' gestation","effectByArm":[{"arm":"Progesterone Group","deltaMin":5,"sd":null},{"arm":"Placebo","deltaMin":8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":20},"commonTop":[]}}